CDK13 and melanoma: To assess the role of CDK12 in melanoma cells, we treated five BRAF-mutated melanoma cell lines (Colo829, A375, WM164, WM983A, WM983B) with increasing concentrations of SR-4835, a recently described ATP-competitive inhibitor of CDK12 and CDK13 [18].